Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3293)	12/11/1997 10:00:00 PM
From: JOHN W.	Read Replies (1) \| Respond to of 6136

Agouron sponsored a meeting this week on its premises to discuss their pipeline with a few analyst and update on viracept. A few key points from PW dated 12/09/97: "1. AG3340, (matrix metalloproteinase inhibitor)-Good safety profile with potential for potent anti-tumor effects in combination with chemotherapy. 2. Phase I in advance in advance cancer patients ongoing; 23 evaluable patients demonstarting no significant toxicities; anecdotal evidence of stable disease and tumor shrinkage in 3 patients. 3. Phase II dose ranging studies to be initiated in Q298. 4.Phase II/III studies expected to target two different indications: 5. Hormone refractory prostrate cancer (with mitixantrone, prednisone) 6. Non-small cell lung cancer (with paclitaxel/carboplatin) 7.. NDA filing targeted for FY 2000, (6/99-6/00)."